Royalty Pharma plc (RPRX) Stock Overview
Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.
Royalty Pharma plc (RPRX)
Key Financials
Key Financials
Market Cap
31.2B
P/E Ratio
41.46
EPS (TTM)
$5.25
ROE
0.10%
RPRX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Royalty Pharma plc (NASDAQ: RPRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Royalty Pharma plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of RPRX on the NASDAQ shows an RSI of 79.21, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $65.55 for the NASDAQ listing.
Key metrics behind Royalty Pharma plc's NASDAQ-traded stock include a P/E ratio of 41.46 and a market capitalization of 31.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RPRX on the NASDAQ.